Generation Bio Co. (GBIO)

Market Cap	26.27M
Revenue (ttm)	19.89M
Net Income (ttm)	-131.67M
Shares Out	67.01M
EPS (ttm)	-1.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	402,701
Open	0.3414
Previous Close	0.3469
Day's Range	0.3411 - 0.3933
52-Week Range	0.3160 - 4.3400
Beta	2.78
Analysts	Strong Buy
Price Target	7.33 (+1,774.2%)
Earnings Date	May 12, 2025

About GBIO

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was former...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: GBIO
• Website: https://generationbio.com

Financial Performance

In 2024, Generation Bio Co.'s revenue was $19.89 million, an increase of 236.92% compared to the previous year's $5.90 million. Losses were -$131.67 million, 3.99% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for GBIO stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 1,774.20% from the latest price.

Price Target

$7.33

(1,774.20% upside)

Analyst Consensus: Strong Buy